Helping you find insights on psychedelics as medicine

Papers | Companies | Reports | Events

Leverage our research to stay up-to-date with the
psychedelic transition from trials to practice

Effects of Psilocybin in Obsessive Compulsive Disorder
This study will test the feasibility, safety, and evidence for the efficacy of psilocybin administration in participants with obsessive-compulsive disorder (OCD).
Category: Trials
Published: 2022-10-05
Psilocybin for the Treatment of Veterans With Post-Traumatic Stress Disorder
The primary aim of this study is to assess the safety and efficacy of psilocybin-assisted therapy in the treatment of post-traumatic stress disorder in United States military Veterans.
Category: Trials
Published: 2022-10-05
PAPR: PAP + MBSR for Front-line Healthcare Provider COVID-19 Related Burnout (PAPR)
This is an open-label randomized study looking at an 8-week Mindfulness-Based Stress Reduction (MBSR) curriculum vs. an 8-week MBSR curriculum + a group psilocybin-assisted psychotherapy intervention for frontline healthcare providers struggling with symptoms of depression and burnout associated with the SARS-CoV-2 pandemic.
Published: 2022-10-05
Blossom Update – October 2022
Back from ICPR, this is the update blog of Blossom for October 2022. New visualisations, extra data in the database & request for feedback.
Category: Blossom Updates
Published: 2022-10-05
Self-Transcendent Positive Emotions as a Potential Mechanism Underpinning the Effects of Meaningful Psychedelic Experiences on Connectedness to Nature
This retrospective survey (n=236) of those who had a meaningful psychedelic experience finds that self-transcendent positive emotions (STPE) predicted positive changes in connectedness to nature. The proposed mechanism (through exploratory analysis of the data) suggests that acute STPE can lead to experiencing more of that in daily life, which leads to feeling more connected to the natural world.
Category: Papers
Published: 2022-10-04
Real-world experience of esketamine use to manage treatment-resistant depression: A multicentric study on safety and efficacy (REAL-ESK study)
This first open-label real-world study (n=116) of esketamine (Spravato, up to 84mg, multiple dosings) finds similar positive outcomes as previous clinical trials. At three months, the response rate (64%) and remission (41%) for those with treatment-resistant depression are impressive. Only 3% of participants dropped out of the study because of side effects.
Category: Papers
Published: 2022-10-04
Research abuses against people of colour and other vulnerable groups in early psychedelic research
This review of early psychedelic studies (the 50s-70s, s=48) finds that most (77%) would not pass ethical review today. The errors made in early research were extensive dosing, lack of consent, inadequate setting, and lack of scientific hypotheses. The authors make restorative justice and cultural competency suggestions.
Category: Papers
Published: 2022-10-04
Bespoke library docking for 5-HT2A receptor agonists with antidepressant activity
This chemistry paper (2022) simulates the docking of 75 million molecules (tetrahydropyridines, THP) on the serotonin 2a (5-HT2a) receptor. The initial screening led to 17 molecules that were further refined down to two molecules ((R)-69 & (R)-70). These two had antidepressant effects (in mice) but didn't show (acute) psychoactive activity (head-twitch response, change in movement).
Category: Papers
Published: 2022-10-04
Associations between MDMA/ecstasy use and physical health in a U.S. population-based survey sample
This observational survey study (n≈750k) finds that those Americans who use MDMA have a more favourable body mass, fewer heart conditions, cancer, hypertension, or diabetes. As always, correlation doesn't equal causation. The authors controlled for confounding variables, but still, other uncontrolled third variable factors (e.g. different personality types even before MDMA use) could explain the correlation.
Category: Papers
Published: 2022-10-04
Effects of Psilocybin in Concussion Headache
This double-blind cross-over trial (n=24) investigates the effect of repeated doses of psilocybin (2x) at varying doses of psilocybin (1 or 10mg) on concussion headache.
Category: Trials
Published: 2022-10-04

partners

Explore Blossom’s Resources

Interconnected & Contextualized Databases

Find the right paper, company, person in over 3.000 entries & 100.000 parameters

Explore Databases

Well-Researched Reports

Survey the psychedelic landscape with reports on 18 topics, 14 compounds & 20 countries

Explore Reports

Timely Insights

Stay in the loop with the latest articles on research & implementation

Explore Insights

Are you new to psychedelics as medicine? Start with our overview →

Subscribe to The Bloom newsletter

A weekly email, sent on Tuesdays, packed with the latest
psychedelic research, news & actionable insights

Work with Blossom

Collaborate on a Report

Put your brand in the spotlight by helping us explore a research area

Collaborate

Associate your brand with our research & get highlighted in the newsletter & search results

Sponsor

Hire our team

Get expert support with writing & editing psychedelic resources

Hire us

partners

“Blossom is democratising access to psychedelic research by presenting papers from a broad range of disciplines in an accessible weekly write-up.”

Josh Hardman

Founder, Psychedelic Alpha

“The Blossom newsletter is a terrific service to the psychedelic research community: a weekly digest that summarises major new findings in a clear, efficient, and informative way. It is a godsend for busy researchers trying to keep abreast of new developments in an increasingly fast-moving field.”

Chris Letheby

Lecturer in Philosophy, University of Western Australia
Author, Philosophy of Psychedelics

“The work that Floris and the Blossom team have done to document, organise and synthesise the emerging psychedelic research has helped me stay up to date with this fast-changing landscape. The Blossom newsletter and database are indispensable resources for anyone who wants to understand the psychedelic science and medicine landscape.”

Zach Heighney

Founder, The Trip Report